49 results
424B3
MBRX
Moleculin Biotech Inc
16 Feb 24
Prospectus supplement
5:19pm
to an expert in chemotherapy who is affiliated with a leading research institute in assessing chemotherapy-related cardiotoxicity. After review … of this data, the independent expert, in their most recent report, concluded that there was no evidence of cardiotoxicity.
The data made available included
8-K
owbgw883
5 Jan 24
Departure of Directors or Certain Officers
5:14pm
8-K
EX-99.1
mhga0bis jp
13 Nov 23
Regulation FD Disclosure
8:05am
8-K
EX-99.1
csbdeg9i 1xcg48
18 Sep 23
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
8:40am
8-K
EX-99.1
iq52 w0dm3
10 Aug 23
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
4:05pm
8-K
EX-99.1
cte e77qr37hm
10 May 23
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
4:07pm
8-K
EX-99.1
is5rsvw zw7d
15 Dec 22
Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock
8:37am
8-K
EX-99.1
y6wvbi8x
10 Nov 22
Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
4:11pm
8-K
EX-99.1
oe3vr5usd3a894anm8oe
4 May 22
Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer
8:15am